Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Erastin: Precision Ferroptosis Inducer for Cancer Biology...

    2026-01-28

    Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

    Overview: Mechanistic Basis and Research Utility

    Erastin (SKU: B1524) from APExBIO is a rigorously characterized small molecule that selectively induces ferroptosis—an iron-dependent, caspase-independent cell death pathway—in tumor cells harboring oncogenic KRAS or BRAF mutations. Unlike classical apoptosis, ferroptosis is driven by lethal accumulation of reactive oxygen species (ROS) and unmitigated lipid peroxidation, largely due to disruption of cellular redox homeostasis via inhibition of the cystine/glutamate antiporter system Xc⁻. This mechanism makes Erastin an indispensable tool for dissecting oxidative stress response pathways, studying the RAS-RAF-MEK signaling axis, and developing next-generation cancer therapies targeting ferroptosis.

    Erastin’s action is twofold: it modulates the voltage-dependent anion channel (VDAC), increasing mitochondrial permeability to pro-oxidant molecules, and it inhibits system Xc⁻, restricting cystine uptake and glutathione synthesis. This dual targeting triggers a cascade of metabolic and transcriptional responses, as highlighted in recent studies of oxidative stress and transcription factor dynamics (Jose et al., 2024), ultimately culminating in iron-dependent, non-apoptotic cell death even in apoptosis-resistant tumor cells.

    Experimental Workflow: Step-by-Step Protocol Enhancements

    1. Preparation and Handling

    • Solubility: Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming. Prepare stock solutions fresh before each use to ensure maximal activity, as Erastin is not stable in solution for long-term storage.
    • Storage: Store Erastin powder at -20°C in a desiccated environment. Minimize freeze-thaw cycles to preserve integrity.

    2. Cell Line Selection and Seeding

    • Select cell lines with defined RAS (e.g., HRAS, KRAS) or BRAF mutations. HT-1080 fibrosarcoma cells are a benchmark model for robust ferroptosis induction.
    • Seed cells to reach 60–80% confluence at the time of treatment to ensure uniform viability and metabolic state.

    3. Treatment Regimen

    • Dilute freshly prepared Erastin stock in complete culture medium to achieve a final concentration of 10 μM. For kinetic studies, consider using 5, 10, and 20 μM to map dose-response relationships.
    • Incubate cells with Erastin for 24 hours (standard condition), with parallel wells for vehicle (DMSO) and positive ferroptosis control (e.g., RSL3) to validate specificity.

    4. Readouts and Ferroptosis Confirmation

    • Cell Viability: Deploy MTT, CellTiter-Glo, or IncuCyte live-cell imaging to quantify cytotoxicity and temporal progression of cell death.
    • Ferroptosis Verification: Co-treat with ferrostatin-1 or liproxstatin-1 to rescue cells from death and confirm ferroptosis specificity. Elevated ROS production can be detected using H2DCFDA or C11-BODIPY lipid peroxidation assays.
    • Oxidative Stress Assays: Quantify H2O2 and glutathione (GSH) levels, referencing dynamic ROS responses described by Jose et al. (2024), which emphasize the importance of temporally coordinated transcription factor activation under oxidative stress.

    Protocol Enhancement Tips

    • Consider pre-treating cells with iron chelators (e.g., deferoxamine) or system Xc⁻ inhibitors to validate the iron-dependence and mechanistic pathway of Erastin-induced cell death.
    • For high-throughput screening, Erastin’s robust activity at 10 μM allows multiplexed viability and ROS assays in 96- or 384-well plates with high reproducibility.

    Advanced Applications & Comparative Advantages

    Precision Targeting in RAS/BRAF-Mutant Cancer Models

    Erastin’s selectivity for tumor cells with KRAS or BRAF mutations enables researchers to dissect vulnerabilities unique to these oncogenic contexts. For instance, studies have shown that Erastin-induced ferroptosis is highly effective in RAS-mutant colorectal and pancreatic carcinoma cell lines, providing a platform for investigating synthetic lethality and resistance mechanisms.

    Integration with Redox Signaling and Transcriptional Responses

    Recent work (Jose et al., 2024) has underscored the temporal coordination of transcription factors such as p53, NRF2, and FOXO1 in response to oxidative insults like H2O2. Erastin, by elevating intracellular ROS and perturbing the redox landscape, offers a model system to interrogate the dose- and time-dependent activation of these cytoprotective or pro-death factors. This is especially valuable for exploring the dichotomy between eustress and distress, and for linking ferroptosis with broader oxidative stress adaptation pathways.

    Workflow Synergy and Literature Integration

    Quantified Performance and Experimental Robustness

    • In HT-1080 cells, 10 μM Erastin treatment typically results in >80% reduction in viability within 24 hours, with ferroptosis-specific rescue rates of 70–90% upon co-treatment with Ferrostatin-1, attesting to its selectivity and potency.
    • High-throughput oxidative stress screens report Z’ factors >0.7 for Erastin-treated plates, supporting its use in large-scale compound screening and genetic perturbation studies.

    Troubleshooting and Optimization Tips

    Common Pitfalls and Solutions

    • Low or Variable Cytotoxicity: Ensure Erastin is freshly dissolved in DMSO and thoroughly mixed; confirm cell line genotype for RAS/BRAF status, as wild-type lines may be less sensitive.
    • Poor Solubility or Precipitation: Warm DMSO gently (37°C) and vortex to fully dissolve Erastin. Use filtered stocks to prevent DMSO crystallization at low temperatures.
    • Non-specific Cell Death: Implement rescue experiments with Ferrostatin-1 or Liproxstatin-1 to distinguish ferroptosis from other forms of cell death. Include caspase inhibitors to rule out apoptosis.
    • Batch-to-Batch Variability: Source Erastin exclusively from trusted suppliers like APExBIO, which provides detailed batch QC and validated protocols.

    Assay Optimization Strategies

    • Standardize cell seeding densities and passage number to reduce biological variability.
    • Optimize DMSO vehicle concentrations (≤0.1%) to minimize solvent cytotoxicity.
    • For oxidative stress assays, time-course experiments (e.g., 2, 6, 12, 24 hours) can reveal temporal changes in transcription factor activation and ROS buildup, leveraging insights from Jose et al., 2024.
    • Confirm iron-dependence by supplementing culture with ferric ammonium citrate or using iron chelators as negative controls.

    Future Outlook: Ferroptosis in Cancer Therapy and Beyond

    The discovery and mechanistic elucidation of ferroptosis have energized the search for novel anti-cancer strategies, especially for tumors resistant to apoptosis. As a benchmark iron-dependent non-apoptotic cell death inducer, Erastin continues to empower research at the intersection of redox biology, cancer metabolism, and targeted therapeutics. Ongoing studies are exploring combinations of Erastin with immunotherapies, chemotherapeutics, and nanomedicine platforms to potentiate cancer cell killing in RAS/BRAF-mutant tumors.

    Moreover, the integration of temporal transcription factor profiling with ferroptosis assays opens new avenues for decoding how cells sense and adapt to oxidative stress, and for developing predictive biomarkers of therapeutic response. The continued refinement of Erastin-based workflows, underpinned by supplier reliability and robust QC from APExBIO, will undoubtedly accelerate discoveries in ferroptosis research, cancer biology, and oxidative stress adaptation.

    For researchers seeking to probe the frontiers of iron-dependent, non-apoptotic cell death, Erastin from APExBIO remains the gold standard—proven, precise, and primed for translational impact.